FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2810369514> ?p ?o ?g. }

• W2810369514 endingPage "2740" @default.
• W2810369514 startingPage "2736" @default.
• W2810369514 abstract "Purpose To update evidence-based guideline recommendations for practicing oncologists and others on systemic therapy for patients with human epidermal growth factor receptor 2 (HER2)–positive advanced breast cancer to 2018. Methods An Expert Panel conducted a targeted systematic literature review (for both systemic treatment and CNS metastases) and identified 622 articles. Outcomes of interest included overall survival, progression-free survival, and adverse events. Results Of the 622 publications identified and reviewed, no additional evidence was identified that would warrant a change to the 2014 recommendations. Recommendations HER2-targeted therapy is recommended for patients with HER2-positive advanced breast cancer, except for those with clinical congestive heart failure or significantly compromised left ventricular ejection fraction, who should be evaluated on a case-by-case basis. Trastuzumab, pertuzumab, and taxane for first-line treatment and trastuzumab emtansine for second-line treatment are recommended. In the third-line setting, clinicians should offer other HER2-targeted therapy combinations or trastuzumab emtansine (if not previously administered) and may offer pertuzumab if the patient has not previously received it. Optimal duration of chemotherapy is at least 4 to 6 months or until maximum response, depending on toxicity and in the absence of progression. HER2-targeted therapy can continue until time of progression or unacceptable toxicities. For patients with HER2-positive and estrogen receptor–positive/progesterone receptor–positive breast cancer, clinicians may recommend either standard first-line therapy or, for selected patients, endocrine therapy plus HER2-targeted therapy or endocrine therapy alone. Additional information is available at www.asco.org/breast-cancer-guidelines ." @default.
• W2810369514 created "2018-07-10" @default.
• W2810369514 creator A5007337539 @default.
• W2810369514 creator A5008617978 @default.
• W2810369514 creator A5027028437 @default.
• W2810369514 creator A5032785430 @default.
• W2810369514 creator A5034917686 @default.
• W2810369514 creator A5041961484 @default.
• W2810369514 creator A5044143691 @default.
• W2810369514 creator A5049174232 @default.
• W2810369514 creator A5052023186 @default.
• W2810369514 creator A5070245248 @default.
• W2810369514 creator A5070508240 @default.
• W2810369514 creator A5071749616 @default.
• W2810369514 creator A5077893229 @default.
• W2810369514 creator A5087724207 @default.
• W2810369514 creator A5088119887 @default.
• W2810369514 date "2018-09-10" @default.
• W2810369514 modified "2023-09-25" @default.
• W2810369514 title "Systemic Therapy for Patients With Advanced Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: ASCO Clinical Practice Guideline Update" @default.
• W2810369514 cites W2095623039 @default.
• W2810369514 cites W2118600577 @default.
• W2810369514 cites W2163750567 @default.
• W2810369514 cites W2191632272 @default.
• W2810369514 cites W2549006299 @default.
• W2810369514 cites W2756245626 @default.
• W2810369514 doi "https://doi.org/10.1200/jco.2018.79.2697" @default.
• W2810369514 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29939838" @default.
• W2810369514 hasPublicationYear "2018" @default.
• W2810369514 type Work @default.
• W2810369514 sameAs 2810369514 @default.
• W2810369514 citedByCount "126" @default.
• W2810369514 countsByYear W28103695142017 @default.
• W2810369514 countsByYear W28103695142018 @default.
• W2810369514 countsByYear W28103695142019 @default.
• W2810369514 countsByYear W28103695142020 @default.
• W2810369514 countsByYear W28103695142021 @default.
• W2810369514 countsByYear W28103695142022 @default.
• W2810369514 countsByYear W28103695142023 @default.
• W2810369514 crossrefType "journal-article" @default.
• W2810369514 hasAuthorship W2810369514A5007337539 @default.
• W2810369514 hasAuthorship W2810369514A5008617978 @default.
• W2810369514 hasAuthorship W2810369514A5027028437 @default.
• W2810369514 hasAuthorship W2810369514A5032785430 @default.
• W2810369514 hasAuthorship W2810369514A5034917686 @default.
• W2810369514 hasAuthorship W2810369514A5041961484 @default.
• W2810369514 hasAuthorship W2810369514A5044143691 @default.
• W2810369514 hasAuthorship W2810369514A5049174232 @default.
• W2810369514 hasAuthorship W2810369514A5052023186 @default.
• W2810369514 hasAuthorship W2810369514A5070245248 @default.
• W2810369514 hasAuthorship W2810369514A5070508240 @default.
• W2810369514 hasAuthorship W2810369514A5071749616 @default.
• W2810369514 hasAuthorship W2810369514A5077893229 @default.
• W2810369514 hasAuthorship W2810369514A5087724207 @default.
• W2810369514 hasAuthorship W2810369514A5088119887 @default.
• W2810369514 hasConcept C121608353 @default.
• W2810369514 hasConcept C126322002 @default.
• W2810369514 hasConcept C142724271 @default.
• W2810369514 hasConcept C143998085 @default.
• W2810369514 hasConcept C185926286 @default.
• W2810369514 hasConcept C197934379 @default.
• W2810369514 hasConcept C2775930923 @default.
• W2810369514 hasConcept C2777329042 @default.
• W2810369514 hasConcept C2778087150 @default.
• W2810369514 hasConcept C2779786085 @default.
• W2810369514 hasConcept C2780182762 @default.
• W2810369514 hasConcept C2781164504 @default.
• W2810369514 hasConcept C2781230642 @default.
• W2810369514 hasConcept C530470458 @default.
• W2810369514 hasConcept C535046627 @default.
• W2810369514 hasConcept C71924100 @default.
• W2810369514 hasConceptScore W2810369514C121608353 @default.
• W2810369514 hasConceptScore W2810369514C126322002 @default.
• W2810369514 hasConceptScore W2810369514C142724271 @default.
• W2810369514 hasConceptScore W2810369514C143998085 @default.
• W2810369514 hasConceptScore W2810369514C185926286 @default.
• W2810369514 hasConceptScore W2810369514C197934379 @default.
• W2810369514 hasConceptScore W2810369514C2775930923 @default.
• W2810369514 hasConceptScore W2810369514C2777329042 @default.
• W2810369514 hasConceptScore W2810369514C2778087150 @default.
• W2810369514 hasConceptScore W2810369514C2779786085 @default.
• W2810369514 hasConceptScore W2810369514C2780182762 @default.
• W2810369514 hasConceptScore W2810369514C2781164504 @default.
• W2810369514 hasConceptScore W2810369514C2781230642 @default.
• W2810369514 hasConceptScore W2810369514C530470458 @default.
• W2810369514 hasConceptScore W2810369514C535046627 @default.
• W2810369514 hasConceptScore W2810369514C71924100 @default.
• W2810369514 hasIssue "26" @default.
• W2810369514 hasLocation W28103695141 @default.
• W2810369514 hasLocation W28103695142 @default.
• W2810369514 hasOpenAccess W2810369514 @default.
• W2810369514 hasPrimaryLocation W28103695141 @default.
• W2810369514 hasRelatedWork W100456685 @default.
• W2810369514 hasRelatedWork W1491128979 @default.
• W2810369514 hasRelatedWork W1981602950 @default.
• W2810369514 hasRelatedWork W2054861834 @default.
• W2810369514 hasRelatedWork W2138977450 @default.
• W2810369514 hasRelatedWork W2481553405 @default.

• next